Evaxion A/S — Regulatory Filings 2021

May 13, 2021

6-K 1 tmb-20210513x6k.htm 6-K Enhanced HTML document created with Toppan Merrill Bridge 9.10.0.88 Created on: 5/13/2021 11:30:20 AM (UTC) HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2021

Commission File Number: 001-39950

Evaxion Biotech A/S

(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f

DK-2970 Hoersholm

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Evaxion Biotech A/S (the “Company”) dated May 13, 2021, announcing the Company’s financial results for the three months ended March 31, 2021.

Exhibits

​	​	​
Exhibit		​
No.	​	Description
​	​	​
99.1	​	Press Release dated May 13, 2021.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	Evaxion Biotech A/S
​	​
Date: May 13, 2021	By:	/s/ Glenn S. Vraniak
​	​	Glenn S. Vraniak
​	​	Chief Financial Officer
​	​	​